185 related articles for article (PubMed ID: 23526244)
1. Effect of various forms of postmenopausal hormone therapy on the risk of ovarian cancer--a population-based case control study from Finland.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2013 Oct; 133(7):1680-8. PubMed ID: 23526244
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal hormone therapy-also use of estradiol plus levonorgestrel-intrauterine system is associated with an increased risk of primary fallopian tube carcinoma.
Koskela-Niska V; Pukkala E; Lyytinen H; Ylikorkala O; Dyba T
Int J Cancer; 2015 Oct; 137(8):1947-52. PubMed ID: 25846583
[TBL] [Abstract][Full Text] [Related]
3. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study.
Jaakkola S; Lyytinen HK; Dyba T; Ylikorkala O; Pukkala E
Int J Cancer; 2011 Apr; 128(7):1644-51. PubMed ID: 21280035
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer risk in postmenopausal women using estradiol-progestin therapy - a nationwide study.
Koskela-Niska V; Lyytinen H; Riska A; Pukkala E; Ylikorkala O
Climacteric; 2013 Feb; 16(1):48-53. PubMed ID: 22640598
[TBL] [Abstract][Full Text] [Related]
5. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well.
Lyytinen HK; Dyba T; Ylikorkala O; Pukkala EI
Int J Cancer; 2010 Jan; 126(2):483-9. PubMed ID: 19588504
[TBL] [Abstract][Full Text] [Related]
6. [Hormone therapy and risk for breast cancer in Finnish postmenopausal women].
Lyytinen H; Ylikorkala O
Duodecim; 2011; 127(3):235-42. PubMed ID: 21438346
[TBL] [Abstract][Full Text] [Related]
7. Hormone therapy and different ovarian cancers: a national cohort study.
Mørch LS; Løkkegaard E; Andreasen AH; Kjaer SK; Lidegaard O
Am J Epidemiol; 2012 Jun; 175(12):1234-42. PubMed ID: 22517811
[TBL] [Abstract][Full Text] [Related]
8. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy.
Rahkola-Soisalo P; Savolainen-Peltonen H; Gissler M; Hoti F; Vattulainen P; Ylikorkala O; Mikkola TS
Int Urogynecol J; 2019 Feb; 30(2):251-256. PubMed ID: 29946829
[TBL] [Abstract][Full Text] [Related]
9. Hormone therapy and ovarian cancer.
Mørch LS; Løkkegaard E; Andreasen AH; Krüger-Kjaer S; Lidegaard O
JAMA; 2009 Jul; 302(3):298-305. PubMed ID: 19602689
[TBL] [Abstract][Full Text] [Related]
10. Parity, menopausal hormone therapy, and risk of ovarian granulosa cell tumor - A population-based case-control study.
Bryk S; Katuwal S; Haltia UM; Tapper J; Tapanainen JS; Pukkala E
Gynecol Oncol; 2021 Dec; 163(3):593-597. PubMed ID: 34598830
[TBL] [Abstract][Full Text] [Related]
11. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis.
Shi LF; Wu Y; Li CY
Menopause; 2016 Apr; 23(4):417-24. PubMed ID: 26506499
[TBL] [Abstract][Full Text] [Related]
12. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse.
Rahkola-Soisalo P; Savolainen-Peltonen H; Gissler M; Hoti F; Vattulainen P; Ylikorkala O; Mikkola TS
Menopause; 2019 Feb; 26(2):140-144. PubMed ID: 29994974
[TBL] [Abstract][Full Text] [Related]
14. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey JV; Brinton LA; Leitzmann MF; Mouw T; Hollenbeck A; Schatzkin A; Hartge P
J Natl Cancer Inst; 2006 Oct; 98(19):1397-405. PubMed ID: 17018786
[TBL] [Abstract][Full Text] [Related]
15. Association of ovarian and uterine cancers with postmenopausal hormonal treatments.
Neves-E-Castro M
Clin Obstet Gynecol; 2008 Sep; 51(3):607-17. PubMed ID: 18677154
[TBL] [Abstract][Full Text] [Related]
16. Primary fallopian tube carcinoma risk in users of postmenopausal hormone therapy in Finland.
Koskela-Niska V; Riska A; Lyytinen H; Pukkala E; Ylikorkala O
Gynecol Oncol; 2012 Aug; 126(2):241-4. PubMed ID: 22561401
[TBL] [Abstract][Full Text] [Related]
17. A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
Korhonen K; Auvinen A; Lyytinen H; Ylikorkala O; Pukkala E
Am J Epidemiol; 2012 Feb; 175(4):309-14. PubMed ID: 22287638
[TBL] [Abstract][Full Text] [Related]
18. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
[TBL] [Abstract][Full Text] [Related]
19. Postmenopausal hormone therapy and the risk of breast cancer in Norway.
Román M; Sakshaug S; Graff-Iversen S; Vangen S; Weiderpass E; Ursin G; Hofvind S
Int J Cancer; 2016 Feb; 138(3):584-93. PubMed ID: 26289549
[TBL] [Abstract][Full Text] [Related]
20. The effect of hormone replacement therapy and tibolone on lipoprotein (a) concentrations in postmenopausal women: A systematic review and meta-analysis.
Anagnostis P; Galanis P; Chatzistergiou V; Stevenson JC; Godsland IF; Lambrinoudaki I; Theodorou M; Goulis DG
Maturitas; 2017 May; 99():27-36. PubMed ID: 28364865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
